Evidence map›Paper›PMID 26649025›Full record

ReviewPakistan journal of medical sciences

"OMIC" tumor markers for breast cancer: A review.

Naila Irum Hadi, Qamar Jamal

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pakistan journal of medical sciences. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Theranostic application ofTheranostics · 2020
    Article
  7. Review
  8. Article
  9. Review
  10. Metabolomic profiling of breast tumors using ductal fluid.International journal of oncology · 2016
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Naila Irum HadiDr. Naila Irum Hadi, MBBS, MPhil, PhD fellow. Professor of Pathology, Ziauddin University, Karachi, Pakistan.
Qamar JamalDr. Qamar Jamal, MBBS, MPhil, PhD. Professor of Pathology, Ziauddin University, Karachi, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is a global health issue, and as the tumor burden increases, we need to come up with newer, better technologies which are convenient, cheap, rapid, sensitive with a high specificity. Technological advancements in the field of cancer biomarker has led to the development of techniques such as mass spectrometric analysis and microarray analysis in which genes, proteins and hundreds and thousands of metabolites can be identified with the emergence of genomics, proteomics and metabolomics. This research is focused on finding biomarkers for diagnosis, prognosis, staging, treatment response and targets for chemotherapy, generating a panel of markers which provide better clinical information compared to a single marker in the panel. This review briefly summarizes application of genomics and proteomics followed by key concepts and applications of metabolomics in breast cancer, with the conclusion that an integration of the three "OMIC" technologies may hold the key to future biomarker discovery. SOURCES OF DATA STUDY SELECTION: The information for this review was collected by searching the Google Scholar and PubMed database for English articles published in the period from 2002 to 2015. The search terms included "biomarkers in breast cancer" along with the following search terms: "genomics", "proteomics", "metabolomics", "breast cancer", "mass spectrometry", "molecular markers" and "cancer biomarker". We have endeavored to quote only the primary sources. Titles and abstracts of retrieved studies were assessed first followed by selection and retrieval of selected full text articles.

Indexed as

ASCO – American Society of Clinical OncologyBiomarkerBreast cancerCA – cancer antigenCdx-2 – caudal type homebox 2ER – estrogen receptorFDA – Federal Drug AuthorityGC-TOF-MS – time of flightGenomicsGPCho – glycerophosphocholineHER2 – human epidermal growth factor receptor 2HMDB – Human metabolome databaseKAL1 – Kallman syndrome 1 sequenceKiSS1 – Kisspeptin 1LC/ESI-MS – electrospray ionizationMetabolomicsMINDACT – Microarray InNode Negative Disease may Avoid ChemoTherapy using Mammaprint–NIST – National Institute of Standards and TechnologyPCho – phosphocholinePgR – progesterone receptorProteomicsTAILORx – Trial Assigning Individualized Options for Treatment (Rx)

Identifiers

PMID26649025
PMCPMC4641294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.